Sensus Healthcare, Inc. (SRTS)

Sensus Healthcare manufactures superficial radiation therapy (SRT) devices that treat non-melanoma skin cancers and keloid scars using low-energy X-rays applied directly to the affected tissue. The company’s primary product is the SRT-100 platform, with a newer generation (SRT-100+) and a software-enhanced variant (SRT-100 Vision). The devices deliver radiation in a way that minimizes exposure to underlying healthy tissue, allowing dermatologists and plastic surgeons to treat skin cancers without traditional surgical excision. The technology addresses a genuine clinical need: non-melanoma skin cancers (primarily basal-cell and squamous-cell carcinomas) are extraordinarily common, affecting millions of Americans annually, and traditional treatment — Mohs micrographic surgery — is effective but invasive, expensive, and leaves scars. Superficial radiation therapy offers a non-invasive alternative that works for early-stage tumours and is easier on older patients or those who cannot tolerate surgery. This is the company’s thesis.

The core risk is adoption. A device that works in the lab and is approved by regulators still needs to be adopted by surgeons and dermatologists, reimbursed by insurance companies, and chosen by patients over existing alternatives. Sensus faces entrenched competition: surgeons trained in Mohs surgery often prefer it because it is highly effective, allows for tissue preservation, and yields excellent cosmetic results. The company must convince doctors and patients to try a radiation-based approach instead, which requires building awareness, training physician users, and navigating insurance coverage. Until very recently, the reimbursement environment was hostile. Insurance companies were not convinced that superficial radiation should be reimbursed at a meaningful rate, and without reimbursement, adoption is limited to a small segment of cash-paying patients and academic medical centres.

That reimbursement environment shifted dramatically in November 2024 when the Centers for Medicare and Medicaid Services established distinct billing codes for superficial radiation therapy treatment of non-melanoma skin cancer. This was a major win for Sensus. Medicare reimbursement per treatment increased by over 300 percent compared with the previous treatment codes that covered the same service. This is the kind of regulatory tailwind that can unlock a medical-device company’s growth: suddenly, doctors have a financial incentive to use SRT rather than other approaches, and patients have insurance coverage rather than having to pay out of pocket.

The challenge now is converting that tailwind into actual adoption. Sensus must install systems in dermatology and surgical practices, which requires capital investment from those practices, retraining of staff, and a shift in workflow. The company has been installing systems and reports a growing installed base, but the installed base is still small relative to the universe of practices that treat skin cancer. The company also faces the fact that many dermatologists, especially those who specialize in Mohs surgery, have deep expertise and financial incentives tied to their current approach. Switching to a new technology is disruptive even when reimbursement is favorable.

A second adoption challenge is patient acceptance. Some patients prefer surgery because they understand it and trust it; others may be averse to radiation therapy based on old associations with cancer treatment or fears about radiation exposure. Sensus must educate patients that superficial radiation therapy is genuinely different from the high-dose radiation used in cancer treatment: the doses are much lower, the exposure is localized, and the safety profile is well-established. But overcoming psychological resistance to any radiation-based approach takes time and education.

The financial model is straightforward. Sensus sells capital equipment (the SRT-100 systems) to medical practices, generating upfront revenue and margin. It also generates recurring revenue from the sale of applicators and supplies, and from service contracts. The company’s gross margins are typically high for medical devices, but the company has not achieved profitability because operating expenses (research and development, sales and marketing, general overhead) are large relative to current revenue. The company is essentially betting that adoption will accelerate following the recent Medicare reimbursement decision, driving volume growth that eventually leads to profitability.

The keloid treatment indication is secondary but clinically meaningful. Keloids are raised scar tissue that sometimes develop after injury or surgery, and they are difficult to treat. Surgical removal often leads to keloid recurrence. Sensus’s SRT devices can treat keloids non-invasively with good efficacy, opening a second market segment. However, keloid treatment is a smaller addressable market than non-melanoma skin cancer, so it is unlikely to be the driver of the company’s growth.

The longer-term risk for Sensus is technological displacement. The medical-device world moves quickly, and new approaches to treating skin cancer could emerge: topical immunotherapy agents, photodynamic therapy, or laser-based systems could all compete with or displace SRT. Sensus must remain focused on improving its devices and expanding applications, or risk becoming obsolete. The company has invested in product evolution — the SRT-100+ is a newer, more capable system — but the company is small and capital-constrained relative to larger medical-device companies that could enter the market with superior technology or marketing.

Competition in the non-melanoma skin cancer treatment space is limited but growing. Accellent and others offer alternative modalities, but Sensus has first-mover advantage in the SRT space and now has regulatory validation and reimbursement. The risk is not so much that rivals will displace SRT with a better technology, but that rivals will simply build SRT systems of their own. Medical-device patents protect certain design aspects, but the fundamental technology is defensible only if Sensus continues to innovate and maintain clinical advantages.

To research Sensus as an investment, begin with the 10-K filing (SEC CIK 0001494891), which details revenue by segment and the installed base of SRT systems in clinical use. Watch the quarterly earnings calls for updates on system installations, clinical adoption rates, and any new regulatory milestones or reimbursement developments. Track clinical publications from academic centres using SRT; if published data continues to show strong efficacy and safety, that supports the adoption thesis.

Key metrics are system installation rate (the number of new SRT systems placed with customers each quarter) and utilization rate (the average number of treatments performed per installed system, which indicates whether doctors are actually using the systems). If utilization is flat or declining, it signals that systems are sitting idle and adoption is stalling. Revenue per installed system and gross margin also matter: if revenue per system is declining, it suggests competitive pricing pressure or failure to cross-sell supplies and services.

The macro context for Sensus is positive: non-melanoma skin cancer incidence is increasing (partly due to aging and sun exposure), and demand for non-invasive treatment options is growing. But the company’s success depends entirely on whether dermatologists and patients choose superficial radiation therapy over established alternatives. The recent Medicare reimbursement decision was a critical catalyst, but catalysts are not guarantees. Sensus is a small company with a promising technology in a growing market, but it remains execution-dependent and vulnerable to slower-than-expected adoption or to technological displacement.